Last reviewed · How we verify
NCT04664894
Direct Acting Anti-Viral's In Chronic HCV Patients
trial testing Sofosbuvir in Safety Issues in 511 participants. Completed in 30 May 2019.
30 May 2019
Quick facts
| Lead sponsor | Getz Pharma |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 511 |
| Start date | 15 May 2018 |
| Primary completion | 30 May 2019 |
| Estimated completion | 30 May 2019 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Sofosbuvir — full drug profile →
Conditions studied
- Safety Issues — all drugs for Safety Issues →
Sponsor
Getz Pharma — full company profile →
Who can join
18 and older, any sex, with Safety Issues. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of the study is to determine the safety of DAA's among chronic HCV patients. The outcomes of the study are; To determine the frequency of adverse events while receiving DAAs with or without RBV and/or Pegylated Interferon To calculate the percentage of patients with severity of medical event as per Karch and Lasagna classification To determine the percentage of patient having serious adverse event as per ICH Classification
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04664894
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sofosbuvir
Trials testing the same drug.
- NCT05717400 — Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Inf · Phase 4 · terminated
- NCT04497649 — Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients · Phase 2, PHASE3 · unknown
- NCT04246723 — Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chr · Phase 2 · completed
- NCT04111367 — Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients · Phase 2 · unknown
- NCT03883698 — Safety of Sofosbuvir in People With Advanced Kidney Failure · Phase 3 · completed
Other recruiting trials for Safety Issues
Currently open trials in the same condition.
- NCT06485141 — BeSMART Secure Storage Counseling in the Inpatient Setting · NA · recruiting
- NCT06494527 — A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults · Phase 1 · active not recruiting
- NCT06189170 — Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients · EARLY_PHASE1 · recruiting
- NCT06509490 — NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors · NA · recruiting
- NCT06498167 — Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) · recruiting
Other Getz Pharma trials
Trials by the same sponsor.
- NCT07174297 — Acotiamide vs Itopride in Postprandial Distress Syndrome · Phase 3 · not yet recruiting
- NCT07031141 — Diabetes Foot Africa Region Registry · not yet recruiting
- NCT06706609 — Classification of Adult-onset Diabetes in Five Subgroups in Pakistani Population · not yet recruiting
- NCT05977647 — Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi · Phase 4 · completed
- NCT05644717 — Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04664894 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Getz Pharma
- Last refreshed: 11 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04664894.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing